People · Operator
Named in public records as an officer, director or promoter · active 2024–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Lycia Therapeutics, Inc. | — | Biotechnology | Series D+ | $202.0M | $1.2B | 2024 |
Andrew Gottesdiener at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Andrew Gottesdiener on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Clare Ozawa | 1 | 8 |
| Thomas Woiwode | 1 | 7 |
| Laurent Fischer | 1 | 4 |
| Ming Fang | 1 | 4 |
| William Rieflin | 1 | 4 |
| Aetna Wun Trombley | 1 | 3 |
| TIM ANDERSON | 1 | 3 |
| Clare S. Ozawa | 1 | 1 |
| Thomas S. Woiwode | 1 | 1 |
| Laurent S. Fischer | 1 | 1 |
| Jeremy S. Caldwell | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.